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Background
A vaccine for HIV-1 would ideally block HIV-1 acquisition
as well as durably control viral replication in breakthrough
infections. A recently published study showed that optimal
SIV vaccines can reduce SIV infection risk and setpoint
viral loads following SIV challenges in rhesus monkeys,
and that immunization with SIV Env was required for
blocking acquisition of infection (Nature 2012 482:89-93).
Here we investigate whether CD8+ T lymphocytes from
these vaccinated rhesus monkeys mediate viral inhibition
in vitro and whether these responses predict virologic con-
trol following SIV challenge.
Methods
PBMC from 23 monkeys that received DNA/MVA, MVA/
MVA, Ad26/MVA, or MVA/Ad26 vaccines expressing
SIVsmE543 Gag/Pol/Env were used in CD8+ T-cell-
mediated in vitro viral inhibition assays. CD8-depleted
PBMC were infected with SIVmac251, and viral inhibition
was defined as the log reduction in p27 of cultures of
CD8-depleted PBMC with and without CD8+ T lympho-
cytes. Viral inhibition was correlated with cellular immune
responses and setpoint viral loads using Spearman rank-
correlation tests.
Results
In vitro CD8+ T-cell-mediated viral inhibition prior to
challenge correlated with Gag-specific ELISPOT (P=.002),
total and central memory CD8+ (P<.001 for both), and
total and central memory CD4+ responses (P=.002 and
P=.001, respectively). A trend was observed with Gag-spe-
cific effector memory CD8+ T-cell responses (P=.014;
P<.006 required for significance after multiple comparison
adjustments). Viral inhibition did not correlate with Pol-
or Env-specific cellular immune responses. Moreover, in
vitro viral inhibition prior to challenge inversely correlated
with in vivo setpoint viral loads following challenge
(P=.014).
Conclusion
These data demonstrate for the first time that the in vitro
viral inhibition assay following vaccination is a predictor
of in vivo virologic control following infection. Further-
more, in vitro viral inhibition correlated with Gag-specific,
but not Pol- or Env-specific, cellular immune responses.
These data suggest the importance of including Gag in an
HIV-1 vaccine in which virologic control is desired.
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